These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 24452202)
1. Cryoimmunotherapy with local co-administration of ex vivo generated dendritic cells and CpG-ODN immune adjuvant, elicits a specific antitumor immunity. Alteber Z; Azulay M; Cafri G; Vadai E; Tzehoval E; Eisenbach L Cancer Immunol Immunother; 2014 Apr; 63(4):369-80. PubMed ID: 24452202 [TBL] [Abstract][Full Text] [Related]
2. The Application of Cytidyl Guanosyl Oligodeoxynucleotide Can Affect the Antitumor Immune Response Induced by a Combined Protocol of Cryoablation and Dendritic Cells in Lewis Lung Cancer Model. Zhang M; Yin T; Lu Y; Feng H Med Sci Monit; 2016 Apr; 22():1309-17. PubMed ID: 27092689 [TBL] [Abstract][Full Text] [Related]
4. Enhanced tumor-specific long-term immunity of hemagglutinating [correction of hemaggluttinating] virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides. Hiraoka K; Yamamoto S; Otsuru S; Nakai S; Tamai K; Morishita R; Ogihara T; Kaneda Y J Immunol; 2004 Oct; 173(7):4297-307. PubMed ID: 15383558 [TBL] [Abstract][Full Text] [Related]
5. Tumor ablation plus co-administration of CpG and saponin adjuvants affects IL-1 production and multifunctional T cell numbers in tumor draining lymph nodes. Raaijmakers TK; van den Bijgaart RJE; den Brok MH; Wassink M; de Graaf A; Wagenaars JA; Nierkens S; Ansems M; Scheffer GJ; Adema GJ J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461350 [TBL] [Abstract][Full Text] [Related]
6. Intranasal Administration of Wang Y; An EK; Kim SJ; You S; Jin JO Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638944 [TBL] [Abstract][Full Text] [Related]
7. Route of administration of the TLR9 agonist CpG critically determines the efficacy of cancer immunotherapy in mice. Nierkens S; den Brok MH; Roelofsen T; Wagenaars JA; Figdor CG; Ruers TJ; Adema GJ PLoS One; 2009 Dec; 4(12):e8368. PubMed ID: 20020049 [TBL] [Abstract][Full Text] [Related]
8. Mannose-Modified Liposome Co-Delivery of Human Papillomavirus Type 16 E7 Peptide and CpG Oligodeoxynucleotide Adjuvant Enhances Antitumor Activity Against Established Large TC-1 Grafted Tumors in Mice. Zhao Y; Wang H; Yang Y; Jia W; Su T; Che Y; Feng Y; Yuan X; Wang X Int J Nanomedicine; 2020; 15():9571-9586. PubMed ID: 33293808 [TBL] [Abstract][Full Text] [Related]
9. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide. Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352 [TBL] [Abstract][Full Text] [Related]
10. Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy. VanOosten RL; Griffith TS Cancer Res; 2007 Dec; 67(24):11980-90. PubMed ID: 18089829 [TBL] [Abstract][Full Text] [Related]
11. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy. Merritt RE; Yamada RE; Crystal RG; Korst RJ J Thorac Cardiovasc Surg; 2004 Feb; 127(2):355-64. PubMed ID: 14762342 [TBL] [Abstract][Full Text] [Related]
12. Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis. Xu Z; Ramishetti S; Tseng YC; Guo S; Wang Y; Huang L J Control Release; 2013 Nov; 172(1):259-265. PubMed ID: 24004885 [TBL] [Abstract][Full Text] [Related]
13. Immunotherapy with dendritic cells pulsed with tumor-derived gp96 against murine lung cancer is effective through immune response of CD8+ cytotoxic T lymphocytes and natural killer cells. Shinagawa N; Yamazaki K; Tamura Y; Imai A; Kikuchi E; Yokouchi H; Hommura F; Oizumi S; Nishimura M Cancer Immunol Immunother; 2008 Feb; 57(2):165-74. PubMed ID: 17628800 [TBL] [Abstract][Full Text] [Related]
14. Enhancement of immunologic tumor regression by intratumoral administration of dendritic cells in combination with cryoablative tumor pretreatment and Bacillus Calmette-Guerin cell wall skeleton stimulation. Udagawa M; Kudo-Saito C; Hasegawa G; Yano K; Yamamoto A; Yaguchi M; Toda M; Azuma I; Iwai T; Kawakami Y Clin Cancer Res; 2006 Dec; 12(24):7465-75. PubMed ID: 17189420 [TBL] [Abstract][Full Text] [Related]
15. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Davila E; Kennedy R; Celis E Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660 [TBL] [Abstract][Full Text] [Related]
16. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma. Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330 [TBL] [Abstract][Full Text] [Related]
17. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity. Davila E; Celis E J Immunol; 2000 Jul; 165(1):539-47. PubMed ID: 10861094 [TBL] [Abstract][Full Text] [Related]
18. Co-administration of carcinoembryonic antigen and HIV TAT fusion protein with CpG-oligodeoxynucleotide induces potent antitumor immunity. Woo SJ; Kim CH; Park MY; Kim HS; Sohn HJ; Park JS; Kim HJ; Oh ST; Kim TG Cancer Sci; 2008 May; 99(5):1034-9. PubMed ID: 18294279 [TBL] [Abstract][Full Text] [Related]
19. Synergy between in situ cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic cell vaccine. den Brok MH; Sutmuller RP; Nierkens S; Bennink EJ; Toonen LW; Figdor CG; Ruers TJ; Adema GJ Cancer Res; 2006 Jul; 66(14):7285-92. PubMed ID: 16849578 [TBL] [Abstract][Full Text] [Related]
20. CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction. Garbi N; Arnold B; Gordon S; Hämmerling GJ; Ganss R J Immunol; 2004 May; 172(10):5861-9. PubMed ID: 15128765 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]